These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29855752)

  • 1. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
    Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
    J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies.
    Warnatz K; Jolles S; Agostini C; Vianello F; Borte M; Bethune C; Grigoriadou S; Richter A; Jain R; Lowe DM; Katelaris C; Milito C; Cook MC
    Clin Immunol; 2022 Mar; 236():108938. PubMed ID: 35121105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
    Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
    Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
    Shapiro R
    Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis.
    Shapiro R
    J Clin Immunol; 2010 Mar; 30(2):301-7. PubMed ID: 20082124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study.
    Cowan J; Bonagura VR; Lugar PL; Maglione PJ; Patel NC; Vinh DC; Hofmann JH; Praus M; Rojavin MA
    J Clin Immunol; 2021 Jan; 41(1):66-75. PubMed ID: 33025378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
    Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
    Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations.
    Cozon GJN; Clerson P; Dokhan A; Fardini Y; Sala TP; Crave JC
    Patient Prefer Adherence; 2018; 12():423-429. PubMed ID: 29618922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort.
    Yalcin Gungoren E; Yorgun Altunbas M; Dikici U; Meric Z; Eser Simsek I; Kiykim A; Can S; Karabiber E; Yakici N; Orhan F; Cokugras H; Aydogan M; Ozdemir O; Bilgic Eltan S; Baris S; Ozen A; Karakoc-Aydiner E
    J Clin Immunol; 2024 Aug; 44(8):169. PubMed ID: 39098942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
    Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA
    J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump.
    Wasserman RL; Cunningham-Rundles C; Anderson J; Lugar P; Palumbo M; Patel NC; Hofmann J; Glassman F; Rogers E; Praus M; Rojavin MA
    Immunotherapy; 2022 Nov; 14(16):1315-1328. PubMed ID: 36128795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.
    Nicolay U; Haag S; Eichmann F; Herget S; Spruck D; Gardulf A
    Qual Life Res; 2005 Sep; 14(7):1683-91. PubMed ID: 16119180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
    Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
    Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
    Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
    J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.
    Sanford M
    BioDrugs; 2014 Aug; 28(4):411-20. PubMed ID: 24925799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
    Fasshauer M; Borte M; Bitzenhofer M; Pausch C; Pittrow D; Park M; Gladiator A; Jandus P
    Adv Ther; 2023 Dec; 40(12):5168-5187. PubMed ID: 37751025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.